Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma

• ClinicalTrials.gov Identifier: NCT01675765
• Recruitment Status: Completed
• First Posted: August 30, 2012
• Results First Posted: September 30, 2020
• Last Update Posted: September 30, 2020
• Sponsor: Aduro Biotech, Inc.
• Information provided by (Responsible Party): Aduro Biotech, Inc.

Study Description

Brief Summary:

This clinical trial will evaluate the safety and immune response of the sequential administration cancer vaccine CRS-207 (with or without cyclophosphamide) followed by standard of care chemotherapy (pemetrexed and cisplatin). CRS-207 is a weakened (attenuated) form of Listeria monocytogenes that has been genetically-modified to reduce its capacity to cause disease, while maintaining its ability to stimulate potent immune responses. CRS-207 has been engineered to elicit an immune response against the tumor-associated antigen mesothelin, which has been shown to be present at higher levels on certain tumor cells (such as mesothelioma) than on normal cells. Pemetrexed and cisplatin are the standard chemotherapy regimen to treat malignant pleural mesothelioma. This trial will evaluate whether giving CRS-207 cancer vaccine with chemotherapy will induce anti-tumor immune responses and/or objective tumor response.

Condition or disease	Intervention/treatment	Phase
Malignant Pleural Mesothelioma	Biological: Immunotherapy plus chemotherapy; Biological: Immunotherapy with cyclophosphamide plus chemotherapy	Phase 1

Detailed Description:

Up to 60 subjects will be enrolled in this study. Eligible subjects will receive 2 prime vaccinations of CRS-207 (1×10^9 colony-forming units [CFU] given intravenously [i.v.] over 2 hours) (with or without cyclophosphamide) 2 weeks apart followed 2 weeks later by up to 6 cycles of pemetrexed and cisplatin 21 days apart. Three weeks after completion of chemotherapy, subjects will receive an additional 2 infusions (boost vaccinations) of CRS-207 3 weeks apart. Subjects will be followed every 8 weeks until disease progression by immune-related response criteria. Subjects who continue to meet dosing eligibility may receive additional CRS-207 (with or without cyclophosphamide) infusions (maintenance vaccinations) at each follow-up visit.

Study assessments include blood draws for safety and immune response monitoring and CT scans [with optional fluorodeoxyglucose positron emission tomography (FDG-PET)] or magnetic resonance imaging (MRI) to monitor disease status. In addition, optional tumor biopsies may be performed before, during and after treatment.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 60 participants
• Allocation: Non-Randomized
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase 1B Study to Evaluate the Safety and Induction of Immune Response of CRS-207 in Combination With Pemetrexed and Cisplatin as Front-line Therapy in Adults With Malignant Pleural Mesothelioma
• Actual Study Start Date: September 3, 2014
• Actual Primary Completion Date: September 5, 2018
• Actual Study Completion Date: August 19, 2019

Arms and Interventions

Arm	Intervention/treatment
Experimental: Immunotherapy plus chemotherapy; Weeks 1 and 3: CRS-207 (1 × 10^9 CFU) Weeks 5, 8, 11, 14, 17 and 20 (up to 6 cycles every 21 days): pemetrexed (500 mg/m^2) and cisplatin (75 mg/m^2) Weeks 23 and 26: CRS-207 Maintenance Vaccinations: CRS-207 every 8 weeks (starting at Week 34) until disease progression	Biological: Immunotherapy plus chemotherapy; live attenuated double deleted Lm; Other Names: CRS-207; Listeria; pemetrexed; cisplatin; ALIMTA; Platinol
Experimental: Immunotherapy with cyclophosphamide plus chemotherapy; Weeks 1 and 3: cyclophosphamide (200 mg/m^2), CRS-207 (1 × 10^9 CFU) Weeks 5, 8, 11, 14, 17 and 20 (up to 6 cycles every 21 days): pemetrexed (500 mg/m^2) and cisplatin (75 mg/m^2) Weeks 23 and 26: cyclophosphamide one day before CRS-207 Maintenance Vaccinations: cyclophosphamide one day before CRS-207 every 8 weeks (starting at Week 34) until disease progression	Biological: Immunotherapy with cyclophosphamide plus chemotherapy; live attenuated double deleted Lm; Other Names: CRS-207; Cytoxan; pemetrexed; cisplatin; ALIMTA; Platinol; Listeria

Outcome Measures

Primary Outcome Measures :

1. Number of Subjects Reporting Adverse Events [ Time Frame: From first study dose until 28 days after the final dose (an average of 44 weeks) ]
   Count of subjects with incidences of adverse events.
2. Induction of Immune Response to Mesothelin by Enzyme-linked Immunosorbent Spot (ELISPOT) Assay [ Time Frame: Change over time assessed at multiple time points until disease progression or death (up to 12 months or longer) ]

Secondary Outcome Measures :

1. Objective Tumor Response [ Time Frame: Baseline to measured disease progression or death (up to 12 months or longer) ]
   Objective tumor response was measured using modified Response Evaluation Criteria in Solid Tumors (mRECIST) for assessment of response in malignant pleural mesothelioma (MPM). Per mRECIST for target lesions and assessed by CT: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Stable Disease, those who fulfilled the criteria for neither PR nor PD; Progressive Disease (PD), >=20% increase in the sum of the longest diameter of target lesions.
2. Time to Progression [ Time Frame: From date of randomization until date of documented progression (by modified RECIST or immune-related response criteria) or death, assessed up to 12 months or longer ]
3. Serum Mesothelin as Correlate of Therapeutic Response [ Time Frame: Change over time assessed at multiple time points until disease progression or death (up to 12 months or longer) ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Have histologically confirmed epithelial or biphasic MPM not amenable to potentially curative surgical resection (subjects with biphasic tumors that have a predominantly (≥50%) sarcomatoid component will be excluded)
• Be at least 18 years of age
• Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• Have an anticipated life expectancy of greater than 6 months
• For women and men of childbearing potential, a medically acceptable method of highly effective contraception (oral hormonal contraceptive, condom plus spermicide, or hormone implants) must be used throughout the study period and for 28 days after their final vaccine administration. (A barrier method of contraception must be employed by all subjects [male and female], regardless of other methods.)
• Be willing and able to give written informed consent, and be able to comply with all study procedures
• Have adequate organ function as defined by specified laboratory values

Exclusion Criteria:

• A candidate for curative surgery
• Surgery within 2 weeks prior to dosing
• Prior radiotherapy or biologic therapy
• Treatment with an investigational agent within 4 weeks before dosing
• Prior systemic chemotherapy
• Currently have or have history of certain study-specified heart, liver, kidney, lung, neurological, immune or other medical conditions
• Documented and ongoing brain metastases
• Have any evidence of hepatic cirrhosis or clinical or radiographic ascites
• Have clinically significant and/or malignant pleural effusion
• Known or suspected allergy or hypersensitivity to yeast or any other component of CRS-207 (e.g., glycerol), Platinol or platinum-containing compounds, or pemetrexed
• Used any systemic steroids within 28 days of study treatment
• Use more than 3 g/d of acetaminophen
• An artificial (prosthetic) joint or other artificial implant or device that cannot be easily removed (with some exceptions for dental and breast implants and biliary stents and mediports)
• Infection with HIV or hepatitis B or C at screening
• Any immunodeficiency disease or immunocompromised state or active autoimmune disease or history of autoimmune disease requiring systemic steroids or other immunosuppressive treatment
• Be a woman who is pregnant or breastfeeding
• Unable to avoid close contact with another individual known to be at high risk of listeriosis (e.g., newborn infant, pregnant woman, HIV-positive individual) during the course of CRS-207 treatment until completion of antibiotic regimen
• Conditions, including alcohol or drug dependence, intercurrent illness, or lack of sufficient peripheral venous access, that would affect the patient's ability to comply with study visits and procedures

Contacts and Locations

Locations

United States, California

University of California at San Francisco

San Francisco, California, United States, 94115

United States, Florida

H. Lee Moffitt Cancer Center

Tampa, Florida, United States, 33612

United States, Illinois

University of Chicago Medical Center

Chicago, Illinois, United States, 60637

United States, Maryland

National Cancer Institute

Bethesda, Maryland, United States, 20892

United States, Pennsylvania

University of Pennsylvania Abramson Cancer Center

Philadelphia, Pennsylvania, United States, 19104

Sponsors and Collaborators

Aduro Biotech, Inc.

Investigators

• Principal Investigator: Raffit Hassan, MD; National Cancer Institute (NCI)

  Study Documents (Full-Text)

Documents provided by Aduro Biotech, Inc.:

Study Protocol  [PDF] March 8, 2018

Statistical Analysis Plan  [PDF] May 4, 2018

More Information

Publications:

Le DT, Dubenksy TW Jr, Brockstedt DG. Clinical development of Listeria monocytogenes-based immunotherapies. Semin Oncol. 2012 Jun;39(3):311-22. doi: 10.1053/j.seminoncol.2012.02.008.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Hassan R, Alley E, Kindler H, Antonia S, Jahan T, Honarmand S, Nair N, Whiting CC, Enstrom A, Lemmens E, Tsujikawa T, Kumar S, Choe G, Thomas A, McDougall K, Murphy AL, Jaffee E, Coussens LM, Brockstedt DG. Clinical Response of Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma. Clin Cancer Res. 2019 Oct 1;25(19):5787-5798. doi: 10.1158/1078-0432.CCR-19-0070. Epub 2019 Jul 1.

• Responsible Party: Aduro Biotech, Inc.
• ClinicalTrials.gov Identifier: NCT01675765
• Other Study ID Numbers: ADU-CL-02
• First Posted: August 30, 2012
• Results First Posted: September 30, 2020
• Last Update Posted: September 30, 2020
• Last Verified: September 2020

Keywords provided by Aduro Biotech, Inc.:

Cancer; Cancer vaccine; Listeria monocytogenes; Listeria-based vaccines; Pemetrexed; Cisplatin; T regulatory cells; Mesothelin; Malignant Pleural Mesothelioma; Chemotherapy; Standard of care; Naive; Front-line; Immunotherapy; MPM

Additional relevant MeSH terms:

Mesothelioma; Mesothelioma, Malignant; Adenoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Mesothelial; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Pleural Neoplasms; Lung Diseases; Respiratory Tract Diseases; Cyclophosphamide; Cisplatin; Pemetrexed; Immunologic Factors; Immunosuppressive Agents; Physiological Effects of Drugs; Antirheumatic Agents; Antineoplastic Agents, Alkylating; Alkylating Agents; Molecular Mechanisms of Pharmacological Action; Antineoplastic Agents; Myeloablative Agonists; Enzyme Inhibitors; Folic Acid Antagonists; Nucleic Acid Synthesis Inhibitors